PAVmed Inc. (PAVM)
PAVM Stock Price Chart
Explore PAVmed Inc. interactive price chart. Choose custom timeframes to analyze PAVM price movements and trends.
PAVM Company Profile
Discover essential business fundamentals and corporate details for PAVmed Inc. (PAVM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
27 Jul 2016
Employees
39.00
Website
https://www.pavmed.comCEO
Lishan Aklog
Description
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
PAVM Financial Timeline
Browse a chronological timeline of PAVmed Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.63, while revenue estimate is $48.00k.
Earnings released on 15 May 2026
EPS came in at -$4.42 falling short of the estimated -$0.69 by -540.58%, while revenue for the quarter reached $22.00k , missing expectations by -70.27%.
Earnings released on 26 Mar 2026
EPS came in at -$2.05 surpassing the estimated -$4.50 by +54.44%, while revenue for the quarter reached $52.00k , beating expectations by +108.00%.
Stock split effective on 2 Jan 2026
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2025
EPS came in at -$8.41 falling short of the estimated -$6.01 by -39.93%, while revenue for the quarter reached $5.00k , missing expectations by -60.00%.
Earnings released on 14 Aug 2025
EPS came in at -$0.05 surpassing the estimated -$0.25 by +80.00%, while revenue for the quarter reached $6.00k , missing expectations by -40.00%.
Earnings released on 15 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.29 by +75.86%, while revenue for the quarter reached $8.00k , missing expectations by -20.00%.
Earnings released on 25 Mar 2025
EPS came in at -$0.06 surpassing the estimated -$0.40 by +85.00%, while revenue for the quarter reached $10.00k , missing expectations by -52.38%.
Earnings released on 13 Nov 2024
EPS came in at -$0.54 surpassing the estimated -$1.30 by +58.46%, while revenue for the quarter reached $996.00k , beating expectations by +4.88k%.
Earnings released on 13 Aug 2024
EPS came in at -$0.84 surpassing the estimated -$1.45 by +42.07%, while revenue for the quarter reached $979.00k , missing expectations by -18.42%.
Earnings released on 13 May 2024
EPS came in at -$0.99 surpassing the estimated -$1.67 by +40.72%, while revenue for the quarter reached $1.01m , missing expectations by -3.81%.
Earnings released on 26 Mar 2024
EPS came in at -$1.33 surpassing the estimated -$1.89 by +29.63%, while revenue for the quarter reached $1.05m , beating expectations by +2.84%.
Stock split effective on 7 Dec 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$1.35 falling short of the estimated -$0.14 by -864.29%, while revenue for the quarter reached $791.00k , missing expectations by -28.09%.
Earnings released on 15 Aug 2023
EPS came in at -$1.35 falling short of the estimated -$0.19 by -610.53%, while revenue for the quarter reached $166.00k , missing expectations by -82.53%.
Earnings released on 16 May 2023
EPS came in at -$1.50 falling short of the estimated -$0.21 by -614.29%, while revenue for the quarter reached $446.00k , beating expectations by +93.91%.
Earnings released on 14 Mar 2023
EPS came in at -$2.25 falling short of the estimated -$0.25 by -800.00%, while revenue for the quarter reached $112.00k , missing expectations by -58.52%.
Earnings released on 15 Nov 2022
EPS came in at -$2.25 falling short of the estimated -$0.26 by -765.38%, while revenue for the quarter reached $76.00k , missing expectations by -67.43%.
Earnings released on 16 Aug 2022
EPS came in at -$2.55 falling short of the estimated -$0.23 by -1.01k%.
Earnings released on 12 May 2022
EPS came in at -$2.10 falling short of the estimated -$0.19 by -1.01k%, while revenue for the quarter reached $189.00k , missing expectations by -16.00%.
Earnings released on 29 Mar 2022
EPS came in at -$2.25 falling short of the estimated -$0.15 by -1.40k%, while revenue for the quarter reached $300.00k , missing expectations by -35.14%.
Earnings released on 22 Nov 2021
EPS came in at -$0.68 falling short of the estimated -$0.00 by -51.85k%, while revenue for the quarter reached $200.00k , missing expectations by -25.93%.
Earnings released on 12 Aug 2021
EPS came in at -$1.20 falling short of the estimated -$0.10 by -1.10k%.
PAVM Stock Performance
Access detailed PAVM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
